TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING

PTO	Certification under 3	(IT applicable)	s. E.
[0	EL257995340US	March 21, 2001	-2€
"Ехр	ress Mail" mailing label number	Date of Deposit	0 H Ø
in an	eby certify that this Transmittal letter, enclosed application, and envelope with the United States Postal Service "Express Mail Pe and addressed to: Box Patent Application, Commissioner for	ost Office to Addressee" service under 37 (sed herein, are being deposited CFR 1.10 on the date indicated
		00.1	2
(Type	Cederic Rodgers ed or printed name of person mailing application)	(Signature of person mai	iling application)
(тур	or printed name or person maning apprearion)	(Oignature of person man	ing approacion)
COM	X PATENT APPLICATION MMISSIONER FOR PATENTS hington, D.C. 20231	Attorney	Docket No. TSRI 817.0
TT U.S.		·	•
		Custo	omer Number <u>002387</u>
_Şir:			
Fran	smitted herewith for filing is the utility patent applicatio	n of inventor(s): Paul Schimmel and	Keisuke Wakasugi
L) I i		or not uncompany to the to	
Fand € Lij Lij	entitled: HUMAN AMINOACYL-tRNA SYNTHETA OF ANGIOGENESIS	ISE POLYPEPTIDES USEFUL FO	K THE REGULATION
	Type Of Application		
= 13			
:	This application is:	•	
ij			
IJ	<u>X</u> an original (nonprovisional) application.		
J	a division of prior application Serial No.	·	
n à	 a continuation of prior application Serial No. a continuation-in-part of prior application Serial 		
]	a continuation-in-part of prior application seri		
à	The entire disclosure of the prior application is con application and is hereby incorporated by reference		of the accompanying
	The prior application is assigned of record to:		·
_		•	
2.	Enclosed Application Elements are:		
	X A duplicate copy of this transmittal letter,		
	X specification (including claims and abstract) contain		
	X drawings: 1 copy of	_ sheet(s) of formal drawings, OR	
	X 1 copy oftwenty-five (25)	_ ,,	
	an executed declaration or oath for the utility paten		
	\underline{X} an unexecuted declaration or oath for the utility pat		
	_ a copy of an executed declaration or oath including		olication,
	statement deleting inventor(s) named in the priority	application	
	Microfiche Computer Program		
	X nucleotide and/or amino acid sequence a. X computer readable copy		
	 a. X computer readable copy b. X paper copy 		
	c. X statement verifying above copies		
		•	

TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING Page 2

- Enclosed Accompanying Application Parts are:
 - Preliminary Amendment
 - Claim cancellations are indicated in Preliminary Amendment
 - X one itemized, stamped, and self-addressed postcard for the PTO Mail Room date stamp.
 - English translation document
 - Information Disclosure Statement including Form PTO-1449 and copies of the citations therein.
- Small entity status
 - Applicant claims small entity status. See 37 CFR 1.27.
- 5. Filing Fees (as calculated below)

	(Col. 1)	(Col. 2)			
For:	Number Filed	Number Extra	Rate	Fee	
Basic Fee			And Administration of the second	\$	710
Total Claims	49 — 20	= 29	x \$ 18 =	\$	522
Independent Claims	5 — 3	= 2	x \$ 80 =	\$	160
Multiple Dependent Claim Presented (if applicable) + \$270 =					270
Subtotal					1,662
	\$	N/A			
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2. TOTAL					1,662

- Please charge my Deposit Account No. 15-0508 in the amount of \$_
- X A check in the amount of 1.662.00 to cover the filing fee is enclosed.
- X The Commissioner is authorized to charge payment of the following amounts associated with this communication or credit any overpayment to Deposit Account No. 15-0508:
 - X Additional filing fees under 37 CFR 1.16 or deficiencies in remittances therefor.
 - X Additional processing fees under 37 CFR 1.17 or deficiencies in remittances therefor.
- X ONLY if applicant has partially paid the patent issue fee under 37 C.F.R. §1.18, then the deficiency shall be charged to Deposit Account No. 15-0508, and the Commissioner is authorized to so charge the Deposit Account.
- X The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 15-0508 for any fee that may be due in connection with such a request for an extension of time.

Date: March 21, 2001

Name and Registration No. Talivaldis Cepuritis (Reg. No. 20,818)

Correspondence Address:

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606 Telephone: (312) 580-1180

<u>.</u>..